Recently, apratoxin S10, a novel apratoxin analog that inhibits the growth of two pancreatic cell lines (EC46 and EC68) by inhibiting receptor tyrosine kinases, vascular endothelial growth factor A (VEGF-A), and interleukin-6 [31], has also demonstrated potent inhibition of highly vascularized cell models including hepatocellular carcinoma (Huh-7), renal cell carcinoma (A-498), and neuroendocrine cancer (NCI-H727) [46]. Here, VEGFA is linked to renal cell carcinoma.